Original Article Effect of acupuncture on sleep quality and neurological function in stroke patients with sleep apnea syndrome

Peng Zhang, Lingsu Cheng, Qian Tian, Guang Chen, Chao Chen, Junfeng Xu

Department of Acupuncture, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China

Received January 5, 2021; Accepted February 28, 2021; Epub May 15, 2021; Published May 30, 2021

Abstract: Objective: To investigate the effect of acupuncture on sleep quality and neurological function in stroke patients with sleep apnea syndrome (SAS). Methods: In this prospective study, a total of 88 stroke patients with SAS were randomized into two groups: observation group (44 cases; patients received the western medicine treatment combined with acupuncture) and control group (44 cases; patients were given western medicine treatment only). All patients in both groups were treated for three weeks. The clinical efficacy, sleep quality, apnea-hypopnea index (AHI), cognitive function, neuron-specific enolase (NSE) and S100 calcium binding protein β (S100 β) levels before and after treatment were compared between patients in the two groups. Results: Compared with those before treatment, the sleep latency, sleep duration, sleep efficiency and minimal oxygen saturation (SaO_{2min}) increased, while the longest apnea time and AHI decreased in both groups after treatment. More significant changes were found in the observation group (all P<0.05). After treatment, the overall effective rate in the observation group was higher than that in the control group (P<0.05); serum levels of NSE and S1006 in both groups were lower than those before treatment, and the levels of the observation group were lower than those of the control group (all P<0.05); Montreal Cognitive Assessment (MoCA) scores in both groups were higher than those before treatment, and scores of the observation group were higher than those of the control group (all P<0.05). Conclusion: Western medicine treatment combined with acupuncture can significantly relieve the clinical symptoms of stroke patients with SAS and improve sleep quality and neurological function. Therefore, it is worthy of clinical application.

Keywords: Stroke, sleep apnea syndrome, acupuncture, sleep quality, neurological function

Introduction

Stroke is a major disease leading to disability and death in Chinese people, especially in the elderly [1]. Sleep apnea syndrome (SAS) is a disease of recurrent apnea during sleep caused by airway stenosis and obstruction of the upper respiratory tract, which is mostly accompanied by snoring during sleep and daytime sleepiness. With the development of the disease, it can cause hypoxemia and hypercapnia. In some severe cases, it may lead to respiratory and circulatory failure, resulting in the death of patients [2]. Elderly stroke patients are more likely to develop SAS, which influence not only the sleep quality, but also their neurological function [3].

Western medicine treatment can relieve nocturnal airway obstruction, apnea and other symptoms to a certain extent. Surgical treatment, one of the typical western medicine treatments, produces serious damage to the body, while drug treatment causes significant adverse reactions [4]. According to Traditional Chinese Medicine (TCM), SAS is classified into "drowsiness" and "snoring". Stroke patients have obstructed airways and inhibited lung-gi, which can cause respiratory dysfunction and apnea. From the TCM theory, the repeated collapse of the pharynx during sleep is the main cause of the occurrence of SAS [5]. Acupuncture can improve recurrent pharyngeal collapse through specific acupoint stimulation, which relieves clinical symptoms in patients with SAS [6]. However, there has been no study investigating the effect of acupuncture on neurological function in stroke patients with SAS. This study aims to investigate the effect of acupuncture on

sleep quality and neurological function in stroke patients with SAS.

Materials and methods

General information

In this prospective study, a total of 88 stroke patients with SAS treated in our hospital from February 2019 to January 2020 were randomized into an observation group and a control group, each with 44 cases.

Inclusion criteria: Patients aged from 45 to 70 years; patients who met the diagnostic criteria of stroke and SAS in "Chinese acute ischemic stroke diagnosis and treatment guidelines 2014" and "Guidelines for the diagnosis and treatment of obstructive sleep apnea hypopnea syndrome (2011 Revision)" [7, 8]. Patients who signed informed consent. Exclusion criteria: Patients with severe cognitive impairment or Alzheimer's disease; patients with brain tumors; patients who could not bear acupuncture treatment; patients who were unable to finish the laboratory biochemical examination; patients with chronic insomnia. This study was approved by the ethics committee of our hospital.

Methods

The control group was treated with western medicine, such as edaravone injection (Batch number: 190626, Shandong Luoxin Pharmaceutical Group Co., Ltd., China), Xueshuantong injection (Batch number: 190808, Livzon (Group) Limin Pharmaceutical Factory, China), aspirin enteric-coated tablets (Batch number: 191029, Shanghai Xinyi Bailuda Pharmaceutical Co., Ltd., China), deproteinized calf blood extract for injection (Batch number: 190420, Wuhan Humanwell Pharmaceutical Co., Ltd., China). Treatment lasted for 3 weeks. Acupuncture treatment was added to the patients in observation group apart from the western medicine treatment in the control group. Lianquan point, the main point in this treatment, was punctured by a disposable filiform needle (diameter: 0.3 mm, length: 50 mm) in depth about 50 mm to the direction of the tongue base. Twisting and reinforcing method was applied to manipulate the needle so that it was well settled and retained for 30 min when the patient felt slight numbress and distension of the throat. Another disposable filiform needle was used to slowly puncture into the place about 20 mm near the Lianquan point with the depth about 20 mm. The needle was retained for 30 min as well. A pulse electrotherapy instrument (KWD-808, Shenzhen Senta Times Technology Co., Ltd., China) was connected to the patient with the frequency set at 2 Hz and the current intensity was manipulated catering to the patient's tolerance. The whole treatment was performed for 3 weeks with 30 min/time, once a day before bedtime.

Outcome measures

Main outcome measures: sleep quality of patients was evaluated by Polysomnography (SOMNlab2, Weinmann Medical Technology, Germany) before and after treatment. The sleep latency, sleep duration, the longest apnea and sleep efficiency were recorded and compared between the two groups [9]. Apneahypopnea index (AHI) and the minimal oxygen saturation (SaO_{2min}) of patients was also measured and compared between the two groups before and after treatment by the Polysomnography [9]. Clinical efficacy was evaluated according to AHI and clinical symptoms, which could be divided into five dimensions: cured, markedly effective, effective and ineffective [10]. Cured referred to the cases as snoring and apnea and other clinical symptoms basically disappeared with AHI <5 times/h and SaO_{2min} >90%. Significantly effective referred to the cases as clinical symptoms were significantly alleviated with AHI <20 times/h or at least 50% less than that before treatment. Effective referred to those as clinical symptoms were alleviated and AHI was 25%-50% less than that before treatment. Ineffective referred to those as clinical symptoms and AHI did not meet the above criteria. The overall effective rate = (cured cases + markedly effective cases + effective cases)/total cases ×100%.

Secondary outcome measures: neurological function: about 5 mL of venous blood was drawn before and after treatment, which was centrifuged after coagulation. The serum was isolated to detect serum levels of neuron-specific enolase (NSE) and S100 calcium binding protein β (S100 β) by enzyme-linked immuno-sorbent assay (ELISA). NSE is mainly present in neuroendocrine cells and neurons in the brain. S100 β is the most active molecule in the S100 protein family and is specifically present in cen-

| | 54) | | | |
|-------------------------|--------------------------|-------------------------|------------|-------|
| Index | Observation group (n=44) | Control group (n=44) | χ^2/t | Р |
| Gender (n) | | | 1.137 | 0.286 |
| Male | 24 | 19 | | |
| Female | 20 | 25 | | |
| Age (years) | 56.8±5.3 | 57.4±6.4 | 0.479 | 0.633 |
| BMI (kg/m²) | 23.43±3.22 | 23.20±3.19 | 0.337 | 0.737 |
| Diseases (n) | | | 1.640 | 0.200 |
| Cerebral hemorrhage | 24 | 18 | | |
| Cerebral infarction | 20 | 26 | | |
| Underlying diseases (n) | | | 0.886 | 0.642 |
| Hypertension | 26 | 21 | | |
| Hyperlipidemia | 13 | 15 | | |
| Diabetes | 8 | 10 | | |
| Smoking history (n) | | | 0.463 | 0.496 |
| Yes | 16 | 13 | | |
| No | 28 | 31 | | |
| Drinking history (n) | | | 0.210 | 0.647 |
| Yes | 13 | 15 | | |
| No | 31 | 29 | | |

Table 1. Comparison of general information of patients between the two groups (n, $\overline{x} \pm sd$)

Note: BMI: body mass index.

tral glial cells and glial cells of other types. Therefore, by checking the cerebrospinal fluid or serum levels of both proteins, the neurological changes after brain tissue damage in patients could be reflected [11]. Montreal Cognitive Assessment (MoCA) was used to assess the cognitive function of patients before and after treatment, with a total score of 30 points. The score is positively correlated with the cognitive function [12].

Statistical analysis

SPSS 20.0 was utilized for statistical analysis of data. Count data were expressed as n (%), and χ^2 test was performed for comparison between groups; measurement data in line with the normal distribution were represented as $\bar{x} \pm$ sd. Paired t test was implemented for comparison before and after intervention in the same group; independent samples t test was carried out for comparison between groups. P<0.05 was considered statistically significant.

Result

Comparison of general information of patients between the two groups

There was no statistically significant difference in the general information between the two groups (P>0.05), so the general data were comparable. See **Table 1** for details.

Comparison of sleep quality of patients between the two groups

Compared with those before treatment, the sleep latency, sleep duration and sleep efficiency of patients in both groups increased after treatment, while the longest apnea time was shortened. There were more significant changes in the observation group (all P<0.05). See **Table 2** for details.

Comparison of AHI and SaO_{2min} of patients between the two groups before and after treatment

After treatment, AHI decreased and SaO_{2min} increased in both groups. More significant chang-

es were found in the observation group (all P<0.05). See **Table 3** for details.

Comparison of clinical efficacy between the two groups before and after treatment

The overall effective rate after treatment in the observation group was higher than that in the control group (P<0.05), as shown in **Table 4**.

Comparison of serum levels of NSE and S100β between the two groups before and after treatment

After treatment, the serum levels of NSE and S100 β in both groups were lower than those before treatment, and both protein levels of the observation group were lower than those of the control group (all P<0.05). See **Table 5** for details.

Comparison of MoCA scores between the two groups before and after treatment

After treatment, the MoCA scores of the two groups were higher than those before treatment, and the scores of the observation group were higher than those of the control group (all P<0.05). See **Table 6** and **Figure 1** for details.

| Groups | Sleep latency (min) | Sleep duration (min) | The longest apnea time (s) | Sleep efficacy (%) |
|--------------------------|---------------------------|-----------------------------|----------------------------|---------------------------|
| Observation group (n=44) | | | | |
| Before treatment | 26.53±6.55 | 324.48±30.58 | 70.07±8.84 | 83.38±4.85 |
| After treatment | 40.05±6.06 ^{*,#} | 440.09±39.96 ^{*,#} | 47.70±7.90 ^{*,#} | 90.09±5.49 ^{*,#} |
| Control group (n=44) | | | | |
| Before treatment | 25.89±5.84 | 322.95±35.64 | 69.80±7.96 | 83.10±5.55 |
| After treatment | 35.59±5.48* | 370.95±37.50* | 53.33±6.60* | 85.98±5.83* |

Table 2. Comparison of sleep quality of patients between the two groups ($\overline{x} \pm sd$)

Note: Compared with that before treatment, *P<0.05; compared with the control group after treatment, *P<0.05.

Table 3. Comparison of AHI and SaO_{2min} of patients between the two groups before and after treatment $(\bar{x} \pm sd)$

| (=) | | |
|--------------------------|--------------------------|---------------------------|
| Groups | AHI (times/h) | SaO _{2min} (%) |
| Observation group (n=44) | | |
| Before treatment | 18.49±4.30 | 86.69±4.44 |
| After treatment | 6.09±1.92 ^{*,#} | 94.48±4.93 ^{*,#} |
| Control group (n=44) | | |
| Before treatment | 18.98±4.88 | 87.04±5.29 |
| After treatment | 13.59±4.30* | 90.13±4.30* |
| | | |

Note: Compared with that before treatment, *P<0.05; compared with the control group after treatment, #P<0.05. AHI: Apnea-hyponea index; SaO_{2min}: minimal oxygen saturation.

Discussion

Central nervous system dysfunction in stroke patients can cause the weakness or even loss of throat muscle tone and stiffness of throat muscle, thus resulting in the occurrence of SAS, which is also the main reason why the incidence of SAS in stroke patients is higher than that of ordinary people [13]. Repeated apnea may cause cerebral hypovolemia, which will induce hypoxemia or hypercapnia and seriously endanger patients' life. According to TCM theory, stroke patients have disorder in gi and blood and weakness of muscles in some body parts. Along with pulmonary respiratory dysfunction, their throat are prone to get blocked, which ultimately induces apnea. It is believed in TCM that benefiting the tongue as well as unblocking the throat is the main principle for the treatment of stroke patients with SAS [14].

In this study, after treatment, the sleep latency, sleep duration, sleep efficiency as well as SaO_{2min} increased, the longest apnea time was shortened and AHI decreased in both groups. The overall effective rate after treatment in the

observation group was higher than that in the control group, suggesting that for stroke patients with SAS, western medicine treatment combined with acupuncture can reduce AHI more significantly, thus improving the sleep quality of patients and the overall treatment effect. The differences between the observation group and the control group were statistically significant. Silva et al. studied the effect of western medicine treatment alone and the combined treatment of western medicine and TCM on the sleep quality of patients with SAS respectively, and the results showed that the combined treatment is more effective in the improvement of patients' sleep quality [15]. The study of Shergis et al. pointed out that acupuncture treatment helps to shorten the sleep latency, increase the sleep duration, and improve the sleep efficiency of patients with sleep disorders [16]. This is because acupuncture at Lianquan point is effective in dredging the Ren meridian, and acupuncture at this point can activate meridians, benefit the tongue and unblock the throat, improve pharyngeal muscle tone, promote airway opening, and facilitate the recovery of tongue muscle function, thus achieving positive effects in the treatment of SAS apnea [17, 18].

NSE is mainly in neuroendocrine cells and neurons in the brain. When brain tissues or neurons are damaged, the damaged neurons will secrete large amounts of NSE which enters the blood circulation through the damaged bloodbrain barrier [19]. It is known that S100β level is quite low in serum and cerebrospinal fluid of patients with non-neurological diseases. When brain tissues are injured, central nervous glial cells and other types of glial cells secrete a large amount of S100β proteins and enter the blood vessels through the damaged blood-

| Groups | Cured | Markedly effective | Effective | Ineffective | Overall effective rate |
|--------------------------|------------|--------------------|-----------|-------------|------------------------|
| Observation group (n=44) | 20 (45.45) | 15 (34.09) | 6 (13.64) | 3 (6.82) | 41 (93.18) |
| Control group (n=44) | 14 (31.82) | 12 (27.27) | 8 (18.18) | 10 (22.73) | 34 (77.27) |
| Z/χ^2 | 5.447 | | | | 4.423 |
| Р | 0.142 | | | | 0.035 |

Table 4. Comparison of clinical efficacy between the two groups before and after treatment (n, %)

Table 5. Comparison of serum levels of NSE and S100 β between the two groups before and after treatment ($\overline{x} \pm sd$)

| (= = =) | | |
|--------------------------|--------------------------|----------------------------|
| Groups | NSE (ng/mL) | S100β protein (µg/L) |
| Observation group (n=44) | | |
| Before treatment | 2.87±0.94 | 144.49±10.04 |
| After treatment | 1.22±0.60 ^{*,#} | 97.80±10.47 ^{*,#} |
| Control group (n=44) | | |
| Before treatment | 2.79±0.86 | 143.87±12.30 |
| After treatment | 1.84±0.78* | 113.33±10.99* |

Note: Compared with that before treatment, *P<0.05; compared with the control group after treatment, #P<0.05. NSE: neuron-specific enolase; S100 β protein: S100 calcium binding protein β .

Table 6. Comparison of MoCA scores between the two groups before and after treatment ($\overline{x} \pm sd$, score)

| Groups | MoCA scores | |
|--------------------------|---------------|--|
| Observation group (n=44) | | |
| Before treatment | 22.93±3.33 | |
| After treatment | 26.67±2.90*,# | |
| Congtrol group (n=44) | | |
| Before treatement | 22.50±3.75 | |
| After treatment | 24.85±3.02* | |
| | | |

Note: Compared with that before treatment, $^{*}P<0.05$; compared with the control group after treatment, $^{#}P<0.05$. MoCA: Montreal Cognitive Assessment.




Figure 1. Comparison of MoCA scores between the two groups before and after treatment. Compared with that before treatment, *P<0.05; compared with the control group after treatment, #P<0.05. MoCA: Montreal Cognitive Assessment.

brain barrier, resulting in abnormally increased serum levels [20]. Therefore, it can be concluded that cerebrospinal fluid or serum levels of NSE and S100β are positively correlated with the impairment degree of central nervous system function [21]. In this study, the serum NSE and S100ß protein levels in both groups after treatment were lower than those before treatment, and their levels in the observation group were lower than those in the control group, suggesting that western medicine treatment combined with acupuncture can more significantly enhance the neurological function of stroke patients with SAS. It is consistent with the study results reported by Chavez et al., which demonstrated that acupuncture treatment was more effective than western medicine treatment on the improvement of neurological function of stroke patients [22]. It is speculated that because Lianguan belongs to Ren meridians, and Ren meridians regulate many yin meridians. When Lianguan is punctured, it can stimulate nerves as well as maintain muscle excitability and tranquilize the mind, thus improv-

ing the patient's neurological function. But the specific effect of acupuncture at Lianquan point in regulating neurological function is still not fully elucidated and it needs to be confirmed by more studies.

In addition, this study is single-centered with a limited sample size, and the specific mechanism of acupuncture at Lianquan point in improving neurological function and cognitive function in stroke patients remains to be explored, which requires further studies.

In summary, western medicine treatment combined with acupuncture can significantly relieve the clinical symptoms of stroke patients with SAS, and improve their sleep quality, neurological function and cognitive function, which is worthy of clinical application and promotion.

Disclosure of conflict of interest

None.

Address correspondence to: Junfeng Xu, Department of Acupuncture, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, No. 314 Anshan West Road, Nankai District, Tianjin 300193, China. Tel: +86-022-27432633; Fax: +86-022-27432633; E-mail: xujunfengz1yd@163.com

References

- Ferro JM, Caeiro L and Figueira ML. Neuropsychiatric sequelae of stroke. Nat Rev Neurol 2016; 12: 269-280.
- [2] Li Z, Celestin J and Lockey RF. Pediatric sleep apnea syndrome: an update. J Allergy Clin Immunol Pract 2016; 4: 852-861.
- [3] Yang D, Rundek T, Patel SR, Cabral D, Redline S, Testai FD, Cai J, Wallace DM, Zee PC and Ramos AR. Cerebral hemodynamics in sleep apnea and actigraphy-determined sleep duration in a sample of the hispanic community health study/study of latinos. J Clin Sleep Med 2019; 15: 15-21.
- [4] Xu TT, You DM and Chen X. Non-surgical treatment of obstructive sleep apnea syndrome. Eur Arch Otorhinolaryngol 2018; 275: 335-346.
- [5] Mao T, Zhang J, Qiao Y, Liu B and Zhang S. Uncovering synergistic mechanism of Chinese herbal medicine in the treatment of atrial fibrillation with obstructive sleep apnea hypopnea syndrome by network pharmacology. Evid Based Complement Alternat Med 2019; 2019: 8691608.
- [6] Liu J, Wu YY, Yu XL, Jia HY, Mao QY and Fang JQ. Temporal effect of acupuncture on amino acid neurotransmitters in rats with acute cerebral ischaemia. Acupunct Med 2019; 37: 252-258.
- [7] Chinese Medical Association Neurology Branch and Chinese Medical Association Neurology Branch Cerebrovascular Disease Group. Chinese Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2014. Chin J Neurol 2015; 48: 247-257.
- [8] Sleep disordered breathing group, Chinese respiratory association. Guidelines for Diagnosis and Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (2011 Revision). Chin J Tuberc Respir Dis 2012; 35: 9-12.
- [9] Liang SF, Shih YH, Chen PY and Kuo CE. Development of a human-computer collaborative sleep scoring system for polysomnography recordings. PLoS One 2019; 14: e0218948.
- [10] Yang X, Xiao Y, Han B, Lin K, Niu X and Chen X. Implication of mixed sleep apnea events in

adult patients with obstructive sleep apneahypopnea syndrome. Sleep Breath 2019; 23: 559-565.

- [11] Isgrò MA, Bottoni P and Scatena R. Neuronspecific enolase as a biomarker: biochemical and clinical aspects. Adv Exp Med Biol 2015; 867: 125-143.
- [12] Carson N, Leach L and Murphy KJ. A re-examination of montreal cognitive assessment (MoCA) cutoff scores. Int J Geriatr Psychiatry 2018; 33: 379-388.
- [13] Otto-Yáñez M, Torres-Castro R, Nieto-Pino J and Mayos M. Obstructive sleep apnea-hypopnea and stroke. Medicina (B Aires) 2018; 78: 427-435.
- [14] Lu L, Zhang XG, Zhong LL, Chen ZX, Li Y, Zheng GQ and Bian ZX. Acupuncture for neurogenesis in experimental ischemic stroke: a systematic review and meta-analysis. Sci Rep 2016; 6: 19521.
- [15] Silva M, Lustosa TC, Arai VJ, Couto Patriota TLG, Lira MPF, Lins-Filho OL, Chalegre ST, B BASK, Secundo IV and Pedrosa RP. Effects of acupuncture on obstructive sleep apnea severity, blood pressure control and quality of life in patients with hypertension: a randomized controlled trial. J Sleep Res 2020; 29: e12954.
- [16] Shergis JL, Ni X, Jackson ML, Zhang AL, Guo X, Li Y, Lu C and Xue CC. A systematic review of acupuncture for sleep quality in people with insomnia. Complement Ther Med 2016; 26: 11-20.
- [17] Deng MJ, Liu CY, Xie Y, Zhu JB and Xu ZH. Regularity of clinical application of lianquan (CV 23) in Chinese ancient times according to literature of traditional Chinese medicine. Zhen Ci Yan Jiu 2018; 43: 194-198.
- [18] Qin L, Zhang XP, Yang XC, Cui CH, Shi J and Jia CS. Deep acupuncture of lianquan (CV23) and Yifeng (TE17) in combination with conventional acupuncture of other acupoints is superior to swallowing rehabilitation training in improving post-stroke dysphagia in apoplexy patients. Zhen Ci Yan Jiu 2019; 44: 144-147.
- [19] Topuzova MP, Alekseeva TM, Panina EB, Vavilova TV, Kovzelev PD, Portik OA and Skoromets AA. The possibility of using neuron-specific enolase as a biomarker in the acute period of stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2019; 119: 53-62.
- [20] He Y, Cai Z and Chen Y. Role of S-100β in stroke. Int J Neurosci 2018; 128: 1180-1187.
- [21] Echeverría-Palacio CM, Agut T, Arnaez J, Valls A, Reyne M and Garcia-Alix A. Neuron-specific enolase in cerebrospinal fluid predicts brain injury after sudden unexpected postnatal collapse. Pediatr Neurol 2019; 101: 71-77.
- [22] Chavez LM, Huang SS, MacDonald I, Lin JG, Lee YC and Chen YH. Mechanisms of acupuncture therapy in ischemic stroke rehabilitation: a literature review of basic studies. Int J Mol Sci 2017; 18: 2270.